<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01245894</url>
  </required_header>
  <id_info>
    <org_study_id>VF-20060</org_study_id>
    <nct_id>NCT01245894</nct_id>
  </id_info>
  <brief_title>Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment</brief_title>
  <official_title>Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on the Coronary Microcirculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to measure the effect of low- and high-dose lipid-lowering
      treatment with rosuvastatin on the coronary physiology parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint was the change from baseline in Index of microcirculatory resistance(IMR).</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints were the changes from baseline in Fractional Flow Reserve (FFR) and lipid values.</measure>
    <time_frame>One year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Myocardial Infarction [C14.907.585.500]</condition>
  <arm_group>
    <arm_group_label>Low-dose Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg Rosuvastatin/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin 40mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Rosuvastatin</intervention_name>
    <description>Rosuvastatin 5mg/day for one year</description>
    <arm_group_label>Low-dose Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose Rosuvastatin</intervention_name>
    <description>Rosuvastatin 40mg/day for one year</description>
    <arm_group_label>High-dose Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ST-segment elevation myocardial infarction

          2. no prior treatment with statins and

          3. a non significant lesion in one of the two non-culprit coronary arteries

        Exclusion Criteria:

          1. age below 18 or above 81 years,

          2. unconscious patients,

          3. serum creatinine &gt; 176Î¼mol/L,

          4. hypothyroidism ((TSH &gt; 1.5 x ULN (upper limit of normal)),

          5. current liver disease (ALAT &gt; 2 x ULN),

          6. unexplained creatine kinase &gt; 3 x ULN,

          7. alcohol or drug abuse within the last five years,

          8. prior myopathy or serious hypersensitivity reaction caused by statins,

          9. women with childbearing potential who were not using chemical or mechanical
             contraception,

         10. pregnant or breastfeeding women,

         11. history of malignancy unless a disease-free period of more than five years was
             present,

         12. patients with abnormal lung function test (LFT),

         13. participation in another investigational drug study less than four weeks before
             enrolment in the present study,

         14. treatment with cyclosporine or fibrates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasmus Egede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fuenen</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>MD Rasmus Egede</name_title>
    <organization>Department of Cardiology, Odense University Hospital</organization>
  </responsible_party>
  <keyword>Index of microcirculatory resistance</keyword>
  <keyword>Fractional Flow Reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

